Tag: Novo

CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on ...

CHICAGO — Novo Nordisk’s next-generation obesity injection targeting the amylin hormone showed substantial weight loss in an early study, but ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of ...

Story follows beneath the quote from the extended video below “There’s very little need and this sounds cynical and I’m ...

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell ...

Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading ...

The battle for market share between the two leaders in the booming obesity drug sector has a new data point ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...